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Abstract 
The dystrophin-glycoprotein complex was examined in dystrophin-deficient dogs with golden retriever muscular dystrophy (GRMD) using 
immunoblot and immunofluorescence analysis. The dystrophin-associated proteins were substantially reduced in muscle from dogs with GRMD. 
Interestingly, regression analysis revealed a strong correlation between the amount of u-dystroglycan and serum creatine kinase levels and the 
contraction tension measured for a given peroneus longus muscle. 
Key words: Dystrophin; Dystrophin-glycoprotein complex; Dystrophin-associated protein; Dystroglycan; 
Golden retriever muscular dystrophy 
1. Introduction 
The Duchenne muscular dystrophy (DMD) gene en- 
codes for a 427 kDa protein named dystrophin [ 1,2]. 
DMD gene mutations, deletions or duplications cause 
dystrophin absence or abnormalities in tissues from pa- 
tients with Duchenne or Becker muscular dystrophy, as 
well as mdx mice and dogs with golden retriever muscu- 
lar dystrophy (GRMD) [2-61. Skeletal muscle dystro- 
phin has been isolated as part of a large, tightly associ- 
ated oligomeric complex containing six other sarcolem- 
ma1 proteins, four of which are glycoproteins [7-l 11. The 
dystrophin-glycoprotein complex binds to the cysteine- 
rich and C-terminal domains of dystrophin [12], thus 
linking dystrophin to a highly glycosylated 156 kDa ex- 
tracellular component (a-dystroglycan) [ 131. a-Dystro- 
glycan binds to merosin, the predominant isoform of 
laminin in skeletal muscle [14-171, and dystrophin and 
the dystrophin-glycoprotein complex co-distribute with 
laminin in cultured myotubes [181 and adult cardiac mus- 
cle [19], respectively. Bacterially expressed fusion pro- 
teins corresponding to the putative actin-binding domain 
of dystrophin [20,21] and the dystrophin-glycoprotein 
complex [15] co-sediment with F-actin. Thus, the dystro- 
phin-glycoprotein complex links the actin-based cy- 
toskeleton with the extracellular matrix, which is likely 
to stabilize the sarcolemmal membrane during muscle 
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contraction [22]. At the neuromuscular junction, 
a-dystroglycan serves as the receptor for agrin and thus 
is likely to be involved in acetylcholine receptor cluster- 
ing [23,24] 
The clinical and pathological aspects of dystrophin 
deficiency vary among affected species. DMD and 
GRMD [25-271 are progressive, debilitating diseases. 
With the exception of the diaphragm muscle [28], mdx 
mice exhibit a relatively mild phenotype [29]. Thus, fac- 
tors other than dystrophin deficiency are involved in 
disease progression. Analysis of comparative data from 
DMD patients, mdx mice and GRMD dogs adds to our 
understanding of the effects of dystrophin deficiency. We 
have previously reported a marked reduction of the 
dystrophin-associated glycoproteins in muscle from mdx 
mice, DMD patients and carriers [8,3&32]. Here we 
demonstrate that all dystrophin-associated proteins are 
present at greatly reduced levels in GRMD muscle and 
that the reduced amounts of a-dystroglycan show a 
strong correlation with decreased contraction tension. 
2. Materials and methods 
2. I. Animals and preparation of skeletal muscle homogenates and 
membranes 
The skeletal muscle used in this study was obtained from dogs in a 
GRMD colony at North Carolina State University. These dogs origi- 
nated from a single male founder that was also used to establish the 
colony at Cornell University [6,26]. The peroneus longus muscle was 
surgically removed from control and GRMD dogs at 3 months of age 
immediately after acquisition of mechanical data, snap-frozen in liquid 
N,, and stored at -80°C as previously described [33]. Homogenates and 
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KCI-washed total skeletal muscle membranes were individually pre- 
pared [lo] from eight different control and nine different GRMD dogs. DYS 
2.2. Antibodies 
Affinity-purified sheep polyclonal antibodies specific for the 35, 43, 
50, and 59 kDa dystrophin-associated proteins [30]; affinity-purified 
rabbit polyclonal antibodies against the N-terminus or C-terminus of 
dystrophin [l 11; and monoclonal antibody IIH6, specific for a-dystro- 
glycan [ 131 were previously described. Immunofluorescence analysis 
was performed as described [34]. 
- c ._ _ _. 
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2.3. SDS-polyacrylamide gel electrophoresis and immunoblotting 
SDS-PAGE [35] was carried out on 3312% gradient gels in the pres- 
ence of 1% /I-mercaptoethanol and stained with Coomassie blue, or 
transferred to nitrocellulose [36]. Molecular weight standards shown in 
the figures were purchased from BRL. Nitrocellulose transfers were 
stained with polyclonal antisera, affinity-purified polyclonal antibodies 
or monoclonal antibodies as previously described [37]. For autoradi- 
ography, ‘251-labeled secondary antibody was used. Coomassie blue- 
stained gels and autoradiograms were analyzed densitometrically using 
a Molecular Dynamics scanning densitometer. The signal intensities 
were quantitated using ImageQuant software [15] by volume integra- 
tion of a rectangle enclosing the region of the autoradiogram corre- 
sponding to the signal and corrected by subtracting the volume integral 
obtained from an identically sized rectangle located where no signal was 
apparent. The autoradiographic staining intensity of each sample was 
also normalized against the densitometric volume integral of myosin in 
each homogenate determined from a corresponding Coomassie blue- 
stained gel (50 pg homogenate/lane). 
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3. Results and discussion 
On immunoblot analysis of skeletal muscle homoge- 
nates, dystrophin-deficient dogs contained substantially 
reduced amounts of a-dystroglycan as compared to con- 
trols (Fig. 1). The abundance of a-dystroglycan was var- 
iable among the homogenates prepared from dystro- 
phin-negative GRMD skeletal muscle. The average 
staining intensity obtained from the GRMD dogs was 
23% of the average intensity obtained from normal con- 
trol dogs (Table l), a difference which was highly signif- 
icant by Student’s t-test (P c 0.005). After normalizing 
for myosin content of the homogenates, the average 
a-dystroglycan staining intensity in GRMD dogs was 
27% of that in control dogs. In agreement with our find- 
ings in muscle from patients with DMD and mdx mice 
[8,30,31], these results demonstrate that the abundance 
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Table 1 
Autoradiographic intensity of IIH6 staining in control and GRMD 
muscle homogenates 
IIH6 A,,,a IIH6 A,,Jmyosin Azssb 
Control f S.E.M. (n = 8) 2,920 ?r 312 0.702 + 0.087 
GRMD f S.E.M. (n = 9) 669 f 221’ 0.188 + 0.072 
GRMD/control 0.229 0.268 
“Autoradiographic intensity (arbitrary units) of IIH6 staining as de- 
tected using ‘251-labeled goat anti-mouse IgM, autoradiography and 
scanning densitometry. 
“Autoradiographic intensity A,,, (arbitrary units) of IIH6 staining nor- 
malized against myosin intensity Ass5 (arbitrary units) as determined 
from corresponding samples electrophoresed on SDS-polyacrylamide 
gels and stained with Coomassie blue. 
‘Significantly different from controls by Student’s t-test (P < 0.005). 
Fig. 1. Relative abundance of a-dystroglycan in GRMD skeletal mus- 
cle. Shown are nitroceliulose transfers of SDS-polyacrylamide gels con- 
taining 500 pg of skeletal muscle homogenates from two normal control 
(NORM) and four dystrophic (GRMD) dogs which were stained with 
polyclonal antibody to dystrophin (DYS) or monoclonal antibody IIH6 
to cc-dystroglycan (156-DAG). Molecular weight standards (x lo-‘) are 
indicated on the left. 
of a-dystroglycan was decreased by more than 72% in 
dystrophin-deficient GRMD dog muscle. 
Immunofluorescence analysis localized all compo- 
nents of the dystrophin-glycoprotein complex to the sar- 
colemma of normal dog skeletal muscle (Fig. 2). In con- 
trast, dystrophin was absent and all dystrophin-associ- 
ated proteins were reduced in GRMD dog skeletal mus- 
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Fig. 2. Immunohistochemical nalysis of the dystrophin-glycoprotein complex in GRMD skeletal muscle. Shown are serial transverse sections (7 pm) 
from a normal control (NORM) or dystrophic (GRMD) dog stained with a polyclonal antibody to the N-terminus of dystrophin (DYS), or 
affinity-purified polyclonal antibodies to a-dystroglycan (156-DAG), 59 kDa dystrophin-associated protein (59-DAP), 50 kDa dystrophin-associated 
glycoprotein (50-DAG) B-dystroglycan (43-DAG) and 35 kDa dystrophin-associated glycoprotein (35-DAG) (magnification x 144). 
cle (Fig, 2) confirming that the dystrophin-glycoprotein 
complex is adversely affected in GRMD. These data are 
consistent with immunoblot analysis of normal dog and 
GRMD skeletal muscle membranes (not shown). 
DMD patients, mdx mice and GRMD dogs all exhibit 
grossly elevated serum creatine kinase levels [25,29,38]. 
Cox et al. [39] demonstrated that over-expression of 
dystrophin in transgenic mdx mice restored all dystro- 
phin-associated proteins and serum creatine kinase to 
normal levels. In agreement with these previous findings, 
linear correlation analysis of pooled data for GRMD 
and control serum creatine kinase measurements (Table 
2) demonstrated that the amount of cz-dystroglycan cor- 
related negatively with the measured creatine kinase lev- 
els (r = -0.823). Furthermore, data from GRMD ani- 
mals correlated more strongly (r = -0.576) than did that 
of controls (Y = 0.229). 
Statistical analysis of contraction tension and kinetics 
data has shown peroneus longus muscles of 3-month-old 
GRMD dogs exhibit significantly reduced twitch and 
Table 2 
Correlation analysis of a-dystroglycan content with various parameters 
tetanic tension, as well as more pronounced post-tetanic 
potentiation compared to control muscles [33]. Linear 
correlation analysis of pooled data from GRMD and 
control peroneus longus muscle (Table 2) demonstrates 
that the amount of cc-dystroglycan correlated positively 
with the measured twitch tension (r = 0.841), tetanic ten- 
sion (r = 0.771), and negatively with the measured post- 
tetanic potentiation (r = -0.660). Data from GRMD 
muscle correlated more strongly for twitch and tetanic 
tension and potentiation than did that of control muscle 
(Table 2). Pooled data did not correlate with the meas- 
ured contraction (r = 0.139) or relaxation (r = -0.126) 
times. When evaluated alone, GRMD contraction 
(r = 0.579) and relaxation (r = 0.569) times correlated 
positively. However, control contraction time did not 
correlate (r = 0.056), while relaxation time correlated 
negatively (r = -0.546). The significance of this finding 
is not clear. Contraction and relaxation times of some 
severely affected GRMD dogs are markedly prolonged 
at later ages [33]. Accordingly, a negative correlation 
Pooled GRMD & Control GRMD 
r (IIH6 ASBS) vs.: r (IIH6 A,,,) vs.: 
Control 
r (IIH6 A,,,) vs.: 
Serum creatine kinase (IU/L) -0.823 
Twitch tension* +o.s41 
Tetanic tension* +0.771 
Post-tetanic potentiation (%) -0.660 
Contraction time (ms) +0.139 
l/2 relaxation time (ms) -0.126 
*Normalized against peroneus longus weight (g/g). 
-0.576 +0.229 
+0.644 +0.134 
+0.644 +0.105 
-0.405 +0.253 
+0.579 +0.056 
+0.569 -0.546 
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between these parameters and a-dystroglycan might 
have been expected. These data suggest that the loss of 
a-dystroglycan correlates with the decreased force-gen- 
erating capacity of GRMD muscle and may also have a 
role in the altered kinetics of contraction previously ob- 
served for GRMD muscle [33]. 
The results of this study demonstrate that dystrophin- 
associated glycoproteins are substantially and signifi- 
cantly reduced in muscle from genetically defined dogs 
with GRMD. Our results demonstrate that the loss of 
dystrophin-associated glycoproteins is common to 
GRMD, DMD and mdx mice [8,30,31], therefore con- 
firming the GRMD dog as an excellent model for human 
DMD. Furthermore, linear correlation analysis between 
a-dystroglycan and serum creatine kinase, and several 
mechanical parameters points towards a relationship be- 
tween the loss of ol-dystroglycan and reduced force-gen- 
erating capacity of GRMD muscle. This observation is 
particularly relevant with respect o DMD in which overt 
muscle weakness is a distinguishing feature [38] and per- 
haps even surprising in light of the fact that there is no 
evidence supporting a direct role for the dystrophin- 
glycoprotein complex in force generation by muscle. 
Dystrophin expression also correlates with certain im- 
munocytochemical and histopathologic parameters in 
DMD [40]. Finally, our results complement and extend 
the findings of Cox et al. [39], who demonstrated that 
expression of dystrophin in the diaphragm muscle of 
transgenic mdx mice resulted in restoration of the dystro- 
phin-glycoprotein complex and recovery of normal con- 
tractile performance. 
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